Showing recent highlights
What's New
PubMed · July 1, 2026
Researchers found that a traditional herbal formula called Kunduan Yimu Decoction may help reduce joint inflammation and other symptoms in people with rheumatoid arthritis — a condition where the immune system mistakenly attacks the joints — possibly by influencing a tiny molecule in the body that helps cells clean up damage and keep inflammation in check. The herbal formula was compared to methotrexate, a commonly used medication for rheumatoid arthritis, in a small study of 66 patients over 12 weeks. This is early research and hasn't yet changed treatment guidelines.
Medications
ScienceDaily · June 1, 2026
A study found that abatacept (brand name Orencia), a drug that works by calming part of the immune system, helped delay the development of rheumatoid arthritis — a condition where the body's immune system attacks the joints — by up to four years in people who were considered high-risk for developing it. Remarkably, researchers found this protective effect continued long after people had stopped taking the medication, even though treatment only lasted one year. This appears to be a new and emerging option being explored for people at risk of rheumatoid arthritis, though it is not yet an established recommendation.
Ask your doctor: Ask the doctor whether abatacept might be something the patient should consider if the patient is at high risk for developing rheumatoid arthritis, especially since the study showed it delayed the disease for years even after stopping the medicine.
What's New
PubMed · June 1, 2026
Researchers found that special shoe inserts called foot orthoses can help reduce pressure on the front of the foot — which matters for people with rheumatoid arthritis because that extra pressure can cause pain and even skin sores over time. However, the review also uncovered a surprising gap: no studies have actually tested whether these inserts can help stretch tight calf muscles, even though stiff calves are thought to make forefoot pressure worse. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — who took a more targeted type of JAK inhibitor (specifically ones that focus on a single pathway called JAK1, such as upadacitinib or filgotinib) were less likely to stop their medication compared to those on broader JAK inhibitors like tofacitinib or baricitinib, mainly because the targeted versions seemed to work better for more people over time. The difference in side effects between the two types was not significant, meaning neither group stopped their medication due to side effects at notably different rates. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether upadacitinib or filgotinib might be better options for the patient to stay on longer compared to tofacitinib or baricitinib for treating rheumatoid arthritis.
Lifestyle
PubMed · June 1, 2026
Researchers found that certain lifestyle habits and other health conditions people already have — such as smoking, obesity, or depression — may be linked to a harder-to-treat form of rheumatoid arthritis, a disease where the immune system attacks the joints causing pain and swelling. The study pooled results from multiple observational studies to measure how strongly each of these factors was connected to cases where standard treatments weren't working well. No single food or exercise was singled out — instead, the research looked at a broad picture of daily habits and existing health conditions together.
What's New
PubMed · June 1, 2026
A study found that a structured talk therapy program called the Unified Protocol — which teaches people skills to manage difficult emotions — helped people with rheumatoid arthritis (a condition where the immune system attacks the joints, causing pain and inflammation) feel less anxious, less depressed, and less stressed. Researchers also found that getting better at handling emotions seemed to be a key reason why people felt improvement, and that the therapy helped reduce 'pain catastrophizing' — meaning people were less likely to dwell on pain or see it as unbearable. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · June 1, 2026
According to European Alliance of Associations for Rheumatology (EULAR) guidelines, people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — have a range of treatment options, including older standard medicines as well as newer biological and targeted drugs, and their doctor can choose based on what works best for each individual. EULAR guidelines also now consider approaches like using joint tissue samples or drug level monitoring to help guide treatment decisions, moving toward more personalized care. This matters because finding the right treatment sooner can help protect joints from long-term damage and improve day-to-day life.
Guidelines
PubMed · June 1, 2026
According to EULAR (the European Alliance of Associations for Rheumatology) guidelines, people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — should be aware that different medications carry different infection risks, which matters when choosing a treatment plan with their doctor. For example, biological medicines (injections or infusions that target specific parts of the immune system) appear to carry a higher risk of serious infections than older oral medications, and one newer class of medicines called JAK inhibitors carries a higher risk of shingles compared to those biological medicines. This kind of safety information helps patients and their doctors have more informed conversations about which treatment option makes the most sense for each person's situation.
Guidelines
PubMed · June 1, 2026
According to European Alliance of Associations for Rheumatology (EULAR) guidelines, people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — should typically start treatment with a medicine called methotrexate, often paired briefly with steroids to help control inflammation quickly. The guidelines also outline when doctors might consider switching to more advanced treatments, such as biologic or targeted therapies, based on how well a patient is responding. This matters because following a clear, step-by-step treatment plan — including regular check-ins to hit specific health targets — gives people the best chance of keeping their joints healthy and maintaining a good quality of life.
Ask your doctor: Ask the doctor whether the patient's current rheumatoid arthritis treatment plan follows the 2025 European guidelines for managing the condition with drugs like methotrexate.
What's New
PubMed · June 1, 2026
Researchers found that most people newly diagnosed with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — were able to stop taking a steroid called prednisolone after using it for just a short period to help manage symptoms while their main treatment kicked in. In fact, about 84% had stopped taking it within 7 weeks, and 95% had stopped within 2 years. This matters because long-term steroid use can have unwanted side effects, so being able to stop early is generally seen as a good outcome. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 28, 2026
Researchers found that in people with early, undifferentiated arthritis — joint inflammation that hasn't yet been confirmed as rheumatoid arthritis — starting treatment with baricitinib (a medication that calms the immune system) reduced joint disease activity more effectively after 3 months than taking standard anti-inflammatory pain relievers alone. Interestingly, by the end of 12 months, patients who had taken methotrexate (a common arthritis medication) showed the lowest disease activity overall, suggesting that getting ahead of the disease early with stronger treatment may have lasting benefits. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · May 26, 2026
A study found that people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — who followed either a Mediterranean-style diet or standard healthy eating guidelines for 12 weeks shifted their eating patterns in a more anti-inflammatory direction, meaning their diet was less likely to promote inflammation in the body. The people whose diets improved the most were eating significantly more omega-3 fatty acids (found in oily fish like salmon), dietary fiber (from fruits, vegetables, and whole grains), and vitamins A and E compared to those whose diets stayed more inflammatory. However, researchers found that these dietary changes did not produce statistically significant improvements in how patients reported feeling day-to-day, such as their pain or quality of life scores.
What's New
PubMed · May 26, 2026
Researchers found that people with rheumatoid arthritis — a condition where the immune system attacks the joints — who had weaker grip strength also tended to have a smaller motor cortex, which is the part of the brain that controls movement. This suggests that weak hands in rheumatoid arthritis may not just be about damaged joints, but could also reflect changes happening in the brain itself. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · May 20, 2026
Researchers found that people with rheumatoid arthritis and similar conditions who need surgery face a tricky balancing act with their arthritis medications, known as DMARDs — a group that includes drugs like methotrexate as well as newer biologic treatments. These medications help control joint inflammation, but because they also affect the immune system, there are concerns they might raise the risk of infections after surgery, while stopping them can cause arthritis symptoms to flare back up. Researchers looked at whether pausing or continuing these medications around the time of surgery was safer, but as of early 2025, clear answers are still being worked out.
Ask your doctor: Ask the doctor whether the patient should stop or continue taking their DMARD medications before and after surgery, and what the risks and benefits are of each approach.
What's New
PubMed · May 20, 2026
Researchers are looking into what happens when people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — slowly reduce or stop certain powerful medications once their symptoms are well under control. The goal is to understand whether cutting back on these drugs is safe and effective, or whether it raises the risk of symptoms coming back. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 20, 2026
Researchers found that people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — who used a small, mild electrical brain stimulation device at home for four weeks reported noticeably more pain relief than those using a fake (inactive) version of the device, and they also used fewer pain medications. The device, called transcranial direct current stimulation, delivers a tiny electrical current to the scalp and is thought to gently change how the brain processes pain signals. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 17, 2026
Researchers found that two different types of medications used for rheumatoid arthritis — filgotinib (a JAK inhibitor) and tocilizumab (an IL-6 inhibitor), both of which work by calming the immune system in slightly different ways — showed similar results in reducing joint pain and disease activity over 12 weeks, with about 38–46% of patients in each group seeing meaningful improvement. One interesting note was that patients taking filgotinib reported feeling better slightly sooner, though that early difference faded over time. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 10, 2026
Researchers looked at 73 animal studies and found that a traditional heat-based therapy called moxibustion — where a dried herb called mugwort is burned near specific spots on the body — appeared to reduce joint swelling and inflammation in animals with a condition similar to rheumatoid arthritis, a disease where the body's immune system attacks its own joints. The therapy seemed to work by calming certain "alarm signals" in the body that drive inflammation, which is interesting because it might one day help scientists understand new ways to ease the pain and joint damage that people with rheumatoid arthritis experience. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether moxibustion, which is a traditional Chinese medicine treatment using mugwort heat on specific body points, might be something worth trying alongside the patient's current rheumatoid arthritis treatment.
What's New
PubMed · May 9, 2026
Researchers found that certain natural variations in a person's genes can affect how well their body handles methotrexate, a common medication used to treat rheumatoid arthritis — meaning some people may be more likely to experience side effects or find the drug less effective based on their genetic makeup. For example, people with a specific gene variation called MTHFR 677T appeared to have a higher risk of toxic side effects, while another variation was linked to the drug working less well over time. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 8, 2026
Researchers found that a structured nursing support program — where nurses and patients worked together to improve daily care habits — helped people with rheumatoid arthritis (a condition where the immune system attacks the joints, causing pain and stiffness) manage their blood sugar better while on long-term steroid treatment, which is known to raise blood sugar as a side effect. People in the program also reported less pain, better joint movement, and lower anxiety and depression compared to those who received standard care. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether a structured nursing program that helps the patient manage the patient's medications and track the patient's blood sugar levels might help the patient stick better to the patient's treatment and feel less joint pain.
Medications
PubMed · May 8, 2026
Researchers found that biosimilar versions of tocilizumab — a medication used to treat rheumatoid arthritis (a condition where the immune system attacks the joints, causing pain and swelling) — work just as well as the original brand-name drug, called Actemra. The study looked at data from thousands of patients and found no meaningful differences in how well the medications eased arthritis symptoms, how safe they were, or how often the body developed a reaction against them. This is a new option in the sense that it confirms biosimilars (lower-cost copies of the original drug) are a reliable alternative for people with rheumatoid arthritis.
Medications
PubMed · May 7, 2026
This research looked at low-dose steroid pills (called glucocorticoids, like prednisone) used to ease inflammation in people with rheumatoid arthritis — a condition where the immune system attacks the joints. The study found that taking a small daily dose over two years led to a modest loss of bone density in the lower spine compared to people not taking the steroid, but importantly, the actual rate of broken bones was similar in both groups. This is a safety update rather than a new treatment, helping doctors and patients better understand the bone-related trade-offs of a medication that has been used for rheumatoid arthritis for many years.
Ask your doctor: Ask the doctor whether taking low-dose prednisone for the patient's rheumatoid arthritis could affect the patient's bone density or increase the patient's risk of fractures.
What's New
PubMed · May 1, 2026
Researchers looked at whether tiny molecules in the body called long non-coding RNAs — think of them as little genetic messengers — could help identify rheumatoid arthritis, a disease where the immune system mistakenly attacks the joints. Across 34 small studies, these molecules showed a promising ability to detect the condition, which raises hope that someday a simple blood or tissue test using them might help doctors diagnose rheumatoid arthritis earlier or more accurately. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · May 1, 2026
This research looked at 13 studies involving 548 people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — and found that doing supervised exercise for at least 12 weeks meaningfully reduced foot pain and made it easier to move around and walk. The types of exercise that seemed to help most were water-based exercise (like gentle pool workouts), Tai Chi (a slow, flowing movement practice), and high-intensity interval training, meaning short bursts of harder effort; someone with rheumatoid arthritis could, for example, look into joining a local water aerobics class or a beginner Tai Chi group and aim to stick with it for three months or more. The research suggests that starting a consistent, structured movement routine — even a gentle one — could make a real difference to foot pain and daily mobility for people living with this condition.
What's New
PubMed · May 1, 2026
Researchers looked at data from over 5,000 people with rheumatoid arthritis — a condition where the immune system mistakenly attacks the joints — and found that people diagnosed at age 60 or older may respond less well to certain medications and reach full remission (meaning little to no signs of disease) less often than younger patients. The study also pointed to specific biological signals in joint tissue that might help explain why older immune systems behave differently, which could someday help doctors choose treatments that work better for older patients. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · May 1, 2026
Researchers found that certain medications used to treat rheumatoid arthritis — a condition where the immune system attacks the joints — may also help protect bone strength, which matters because people with rheumatoid arthritis are already at higher risk of fractures due to the disease weakening their bones over time. The review looked at dozens of studies and found that newer, more targeted treatments appeared to have an even greater positive effect on bone density than older standard medications, with early hints that some specific drugs may work better than others. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · April 10, 2026
According to the Latin American Association of Thoracology (ALAT) guidelines, people with rheumatoid arthritis — a condition where the immune system attacks the joints — should be screened early for a related lung condition called interstitial lung disease (ILD), where the lung tissue becomes inflamed and scarred over time. ALAT now recommends that getting joint inflammation under control as quickly as possible is one of the most important steps, because it can help lower the risk of lung disease developing or getting worse. The guidelines also recommend a group of medications called DMARDs — drugs that target the immune system to slow disease — as the foundation of treatment, with additional options available for those whose lung scarring continues to progress.
Ask your doctor: Ask the doctor whether the patient should get lung screening tests to check for early signs of lung disease, since people with rheumatoid arthritis can sometimes develop a serious lung condition called interstitial lung disease.
Lifestyle
PubMed · April 6, 2026
In this small study, people with early-stage rheumatoid arthritis received 10 professional hand massage sessions spread across two weeks — roughly one session every day or two. Those who received the massages showed noticeable improvements in hand grip strength and pinch strength (how hard you can squeeze or pinch with your fingers) compared to people who did not receive massage. The study was small and used trained practitioners, so it gives an early but promising signal rather than a definitive answer.
What's New
PubMed · April 3, 2026
Researchers found that certain natural variations in a gene called FPGS — think of it like a tiny spelling difference in your DNA — appear to affect how well people with rheumatoid arthritis respond to a common treatment called methotrexate, and also how likely they are to experience side effects from it. This is interesting because it hints that someday, a simple genetic test might help doctors predict which patients will benefit most from methotrexate and who might need extra monitoring for side effects. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · April 1, 2026
This is a guideline update — a group of 21 experts in Austria worked together between 2023 and 2025 to create practical guidance for doctors managing heart health in people with rheumatoid arthritis and related conditions. The guidelines highlight that chronic joint inflammation raises the risk of serious heart problems like heart attacks or strokes, and they lay out a three-phase plan covering everything from early diagnosis to ongoing monitoring and lifestyle support. This isn't about a single medication, but rather a structured approach to help doctors catch and reduce heart risks earlier in people living with these conditions.
Ask your doctor: Ask the doctor whether the patient's rheumatoid arthritis increases the risk of heart disease and what screening or preventive steps the patient should take because of this.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.